Equities Analysts Set Expectations for AUTL FY2028 Earnings

Autolus Therapeutics plc (NASDAQ:AUTL) – Research analysts at William Blair issued their FY2028 EPS estimates for shares of Autolus Therapeutics in a research note issued on Thursday, March 20th. William Blair analyst M. Phipps expects that the company will post earnings of ($0.18) per share for the year. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.12. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million.

Several other research firms also recently weighed in on AUTL. Needham & Company LLC reissued a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Wells Fargo & Company decreased their price target on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a research note on Friday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Autolus Therapeutics presently has a consensus rating of “Buy” and an average price target of $9.52.

Autolus Therapeutics Stock Performance

NASDAQ AUTL opened at $1.71 on Monday. The company has a market capitalization of $455.02 million, a P/E ratio of -1.41 and a beta of 2.07. The stock has a 50 day moving average price of $2.01 and a 200-day moving average price of $2.88. Autolus Therapeutics has a one year low of $1.56 and a one year high of $6.60.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of AUTL. Hennion & Walsh Asset Management Inc. bought a new position in shares of Autolus Therapeutics in the 4th quarter worth $611,000. Wellington Management Group LLP boosted its position in shares of Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after purchasing an additional 6,330,392 shares in the last quarter. FMR LLC grew its stake in shares of Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after acquiring an additional 5,478,706 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Autolus Therapeutics during the third quarter worth $708,000. Finally, JPMorgan Chase & Co. grew its stake in Autolus Therapeutics by 145.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock valued at $4,663,000 after purchasing an additional 761,008 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.